Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
In: Journal of Neurology, Neurosurgery & Psychiatry, Jg. 89 (2018-10-01), Heft 10, S. 1050-1056
academicJournal
Zugriff:
Objective: Little is known about disease-modifying treatments (DMTs) for multiple sclerosis (MS) and infection risk in clinical practice. We examined the association between DMTs and infection-related medical encounters. Methods: Using population-based administrative data from British Columbia, Canada, we identified MS cases and followed them from their first demyelinating event (1996-2013) until emigration, death or study end (December 2013). Associations between DMT exposure (by DMT generation or class) and infection-related physician or hospital claims were assessed using recurrent time-to-events models, adjusted for age, sex, socioeconomic status, index year and comorbidity count. Results were reported as adjusted HRs (aHRs). Results: Of 6793 MS cases, followed for 8.5 years (mean), 1716 (25.3%) were DMT exposed. Relative to no DMT, exposure to any first-generation DMT (beta-interferon or glatiramer acetate) was not associated with infection-related physician claims (aHR: 0.96; 95% CI 0.89 to 1.02), nor was exposure to these drug classes when assessed separately. Exposure to any second-generation DMT (oral DMT or natalizumab) was associated with an increased hazard of an infection-related physician claim (aHR: 1.47; 95% CI 1.16 to 1.85); when assessed individually, the association was significant for natalizumab (aHR: 1.59; 95% CI 1.19 to 2.11) but not the oral DMTs (aHR: 1.17; 95% CI 0.88 to 1.56). While no DMTs were associated with infection-related hospital claims, these hospitalisations were also uncommon. Conclusion: Exposure to first-generation DMTs was not associated with an altered infection risk. However, exposure to the second-generation DMTs was, with natalizumab associated with a 59% increased risk of an infection-related physician claim. Continued pharmacovigilance is warranted, including an investigation of the DMT-associated infection burden on patient outcomes. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Neurology, Neurosurgery & Psychiatry is the property of BMJ Publishing Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
|
---|---|
Autor/in / Beteiligte Person: | Andreas Wijnands, José Maria ; Zhu, Feng ; Kingwell, Elaine ; Fisk, John David ; Evans, Charity ; Marrie, Ruth Ann ; Zhao, Yinshan ; Tremlett, Helen ; Wijnands, José Maria Andreas |
Zeitschrift: | Journal of Neurology, Neurosurgery & Psychiatry, Jg. 89 (2018-10-01), Heft 10, S. 1050-1056 |
Veröffentlichung: | 2018 |
Medientyp: | academicJournal |
ISSN: | 0022-3050 (print) |
DOI: | 10.1136/jnnp-2017-317493 |
Schlagwort: |
|
Sonstiges: |
|